UOC
ATXS

UBS O'Connor’s Astria Therapeutics ATXS Stock Holding History

UBS O'Connor’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-129,666
Closed -$1.16M – 344
2024
Q4 		$1.16M Buy
129,666
+5,464
+4% +$58K 0.03% 214
2024
Q3 		$1.37M Buy
124,202
+11,537
+10% +$128K 0.03% 241
2024
Q2 		$1.03M Buy
112,665
+4,545
+4% +$44.4K 0.03% 292
2024
Q1 		$1.52M Buy
108,120
+30,000
+38% +$374K 0.04% 231
2023
Q4 		$600K Sell
78,120
-45,880
-37% -$254K 0.02% 330
2023
Q3 		$925K Buy
124,000
+10,000
+9% +$85.3K 0.02% 342
2023
Q2 		$950K Buy
+114,000
New +$1.32M 0.02% 386

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

UBS O'Connor's ATXS Position: Q1 2025 in Review

UBS O'Connor sold out of Astria Therapeutics (ATXS) in Q1 2025, closing a stake of 129,666 shares — an estimated $1.16M sold.

UBS O'Connor first reported a position in ATXS in Q2 2023 and held it in 7 quarters. The position peaked at $1.52M in Q1 2024. 115 funds tracked by Wall St. Rank hold ATXS as of Q1 2025.

  • UBS O'Connor reported no remaining Astria Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 129,666 Astria Therapeutics shares in Q1 2025, an estimated $1.16M.
  • UBS O'Connor first reported a position in Astria Therapeutics in Q2 2023 and held it in 7 quarters.
  • UBS O'Connor's Astria Therapeutics position peaked at $1.52M in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.